1. No category

Fighting autoimmune disease
The need for a personalized approach
1
2
Autoimmune disease takes many forms,
with varying levels of severity
The prevalence of autoimmune disease
is widespread and significant
Disease is initiated when the body incorrectly mounts
an immune response against its own tissues
100 Billion
1 IN 6 AMERICANS SUFFER
FROM AUTOIMMUNE
DISEASE
IN ANNUAL
HEALTHCARE
COSTS
VS
Globa
la
u
Connective
Tissue
une disease
m
di
im
to
tics
nos
ag
Central Nervous
System
$1
18)
Internal Organs
li
on
IN ANNUAL
HEALTHCARE COSTS
FOR HEART DISEASE
& STROKE
1 IN 13 AMERICANS
SUFFER FROM
HEART DISEASE
20
B il
AUTOIMMUNE DISEASE AFFECTS A RANGE OF
BIOLOGICAL SYSTEMS AND HAVE FLUCTUATING
PATTERNS OF ACTIVITY AND REMISSION
200 Billion
ma
rket (e st
te
a
im
d
VS
Over 80 different forms of autoimmune disease
• Rheumatoid Arthritis (RA)
• Systemic Lupus
Erythematosus (SLE)
• Ankylosing Spondylitis (AS)
• Systemic Sclerosis (SSc)
• Multiple Sclerosis (MS)
• Neuromyelitis Optica (NMO)
• Addison's disease
• Celiac disease
IN ANNUAL
HEALTHCARE
COSTS
1 IN 33 AMERICANS
SUFFER FROM A
FORM OF CANCER
4
Overlapping symptoms make an
accurate diagnosis difficult
Symptom complexity
Advanced screening techniques can
boost the power of diagnostics (Dx)
Developing better biomarkers using the world’s
largest human protein library
Joint pain
Impaired vision
Limb paralysis
Pulmonary
fibrosis
Blindness
Ulcers on
finger tips
Myocarditis
Joint
stiffness
Skin rash
Cognitive
impairment
Fatigue
Nephritis
Numbness
Loss of bladder
control
Seizure
Hardened skin
Symptom areas
Systemic Lupus Erythematosus
Systemic Sclerosis
Rheumatoid Arthritis
Neuromyelitis Optica
Multiple Sclerosis
Ankylosing Spondylitis
5
57 Billion
Diagnostic tools that can unravel this
complexity will improve treatment success
180,000
14,000
CLONES
7,000
GENES
PROTEINS
and applying SeroTag® to identify and differentiate
diseases
SeroTag®
3
• Dermatomyositis
• Graves' disease
• Hashimoto's thyroiditis
• Myasthenia gravis
• Pernicious anemia
• Reactive arthritis
• Sjogren syndrome
• Type I diabetes
• ...
B I DWU
E R D S C
SE D F R
D F R E D
SWE D F
D E R F T
MB E D F
S R EQ F
G E OR G
O
L
T
A
R
G
R
Y
P
G
E
T
R
T
V
N
H
T
L
R
Z
T
C
L
C
Z
B
Y
O
U
H
V
U
V
U
S
S
S
I
R
G
P
H
I
D
G T ROU
I S T E F
J H Z T G
I T I S R
J U I T Z
U SWE D
S U I U Z
O I KMY
FM I K Z
Z
A
F
T
F
C
N
O
E
H
N
R
Z
G
H
G
S
S
G
T
D
H
D
U
D
I
C
F
G
C
D
S
O
Z
T
E
P
E
T
E
R
P
E
I
D
D
E
G
D
D
S
D
S
E
Novel, proprietary biomarkers are found to:
• Specifically identify diseases earlier
• Enable monitoring of progression and prognosis
• Improve disease management
Dx: deciphering complex and overlapping symptoms
for a more specific and accurate diagnosis
6
This approach can also be applied to
improve targeted drug development
Companion Diagnostics (CDx) can help to identify
patient subgroups using disease-specific biomarkers
One size does not fit all
ONLY 50% OF PATIENTS RESPOND TO DRUGS FOR
RHEUMATOID ARTHRITIS
DRUG A
ONLY 40% OF PATIENTS RESPOND TO DRUGS FOR
CARDIAC ARRYTHMIAS
DRUG B
ONLY 20% OF PATIENTS RESPOND TO DRUGS FOR CANCER
Clinicians have to prescribe the perceived best drug,
often with limited diagnostics
DRUG D
DRUG C
CDx can be developed alongside a new drug
CLINICAL TRIAL
PHASES I–III
CDx DEVELOPMENT
DISCOVERY, OPTIMIZATION,
VALIDATION
+
CDx
DRUG A
7
CDx: benefiting all stakeholders, from
patients and clinicians, to payors and pharma
Diagnostics differentiated
Complex symptoms can make an autoimmune
disease diagnosis challenging
Identification of novel biomarkers can help
differentiate disease types
50% of patients do not benefit from their
prescribed medication
CDx allow for relevant patient stratification and
personalized treatment
Drug response varies hugely between individual
patients
Better Dx enable identification of disease stages
and prescription of relevant drugs
The combination of Dx and CDx facilitates a better understanding of
autoimmune disease and its progression, improves the chances of early diagnosis
and ensures the right patient gets the right treatment.
Source material
Autoimmune Statistics. The American Autoimmune Related Diseases Association (AARDA).
http://www.aarda.org/autoimmune-information/autoimmune-statistics
Spear, B. B., Heath-Chiozzi, M. & Huff, J. Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201–204 (2001).
Copyright © 2014 Protagen AG, Dortmund, Germany
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Germany
+49 231 9742 6300
info@protagen.com